HLA-A and melanoma: They concluded that “defining PRAME [Preferentially Expressed Antigen in Melanoma]-specific T cells beyond HLA-A*02-restricted epitopes could be useful when developing T-cell therapeutics for worldwide application”.38 For researchers, being aware that HLA restriction can introduce racial inequality in HLA-based therapeutics could motivate them to systematically incorporate and evaluate techniques to overcome such restrictions, whenever possible.